We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Genomic Studies Reveal Links Between Prostate Cancer and Cardiovascular Disease

By LabMedica International staff writers
Posted on 13 May 2014
Print article
Image: Micrograph of normal prostatic glands and those with prostate adenocarcinoma (upper right portion of image) (Photo courtesy of Wikimedia Commons).
Image: Micrograph of normal prostatic glands and those with prostate adenocarcinoma (upper right portion of image) (Photo courtesy of Wikimedia Commons).
A large-scale statistical evaluation of genomic studies linked to either prostate cancer (PCA) or cardiovascular disease (CVD) risk identified 17 genetic loci that link prostate cancer to risk of developing CVD.

Investigators at Oslo University (Norway) and their colleagues at the University of California, San Diego (USA) applied a genetic epidemiology method based on conjunction false discovery rate (FDR) that combined summary statistics from different genome-wide association studies (GWAS), and allowed identification of genetic overlap between two phenotypes. FDR is a statistical method used in multiple hypotheses testing to correct for multiple comparisons. In a list of findings, FDR procedures are designed to control the expected proportion of incorrectly rejected null hypotheses.

The investigators evaluated summary statistics from large, multicenter GWA studies of PCA (n = 50,000) and CVD risk factors (n = 200,000). CVD risk factors included triglycerides (TG), low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, systolic blood pressure, body mass index, waist-hip ratio, and type II diabetes.

Results published in the April 30, 2014, online edition of the International Journal of Epidemiology revealed that the strongest association between PCA and CVD risk was conditional on LDL and TG. In contrast, the investigators found only weak enrichment conditional on HDL or conditional on the other traits investigated. Conjunction FDR identified altogether 17 loci; 10 loci were associated with PCA and LDL, three loci were associated with PCA and TG and additionally four loci were associated with PCA, LDL, and TG jointly.

"It is fair to say that risk relationships of various sorts have been proposed between prostate cancer and cardiovascular disease, although not comorbidity per se," said contributing author Dr. Ian G. Mills, researcher in the prostate cancer group at the University of Oslo. "There is a lack of consistency across cohorts, however, in size and direction of effects, depending on cardiovascular risk factor considered. The significant risk association with LDL cholesterol and triglycerides versus the other traits at a genetic level was novel and unexpected."

Related Links:

Oslo University
University of California, San Diego


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Signs of multiple sclerosis show up in blood years before symptoms appear (Photo courtesy of vitstudio/Shutterstock)

Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset

Autoimmune diseases such as multiple sclerosis (MS) are thought to occur partly due to unusual immune responses to common infections. Early MS symptoms, including dizziness, spasms, and fatigue, often... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.